HCW Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . HCW Biologics
HCWB Stock  USD 0.97  0.16  14.16%   
HCW Biologics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing HCW Biologics' valuation are provided below:
Gross Profit
166.6 K
Market Capitalization
5.4 M
Enterprise Value Revenue
20.7905
Revenue
832.8 K
Earnings Share
(16.41)
We have found one hundred twenty available fundamental trends for HCW Biologics, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to confirm all of HCW Biologics regular market performance against the performance between 2010 and 2026 to make sure the company can sustain itself next year. As of January 1, 2026, Market Cap is expected to decline to about 657.5 M. In addition to that, Enterprise Value is expected to decline to about 666 M

HCW Biologics Total Revenue

3.73 Million

Check HCW Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among HCW Biologics' main balance sheet or income statement drivers, such as Interest Income of 610.2 K, Depreciation And Amortization of 838.9 K or Interest Expense of 1.2 M, as well as many indicators such as Price To Sales Ratio of 256, Dividend Yield of 0.0 or Days Sales Outstanding of 144. HCW financial statements analysis is a perfect complement when working with HCW Biologics Valuation or Volatility modules.
  
Build AI portfolio with HCW Stock
Check out the analysis of HCW Biologics Correlation against competitors.
For information on how to trade HCW Stock refer to our How to Trade HCW Stock guide.

HCW Biologics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets33.8 M30.2 M19.3 M
Slightly volatile
Other Current Liabilities1.5 M981.9 K996 K
Slightly volatile
Total Current Liabilities31.1 M29.6 M5.4 M
Slightly volatile
Property Plant And Equipment Net24.1 M22.9 M6.3 M
Slightly volatile
Accounts Payable23.4 M22.3 M3.6 M
Slightly volatile
Cash7.8 M4.7 M8.3 M
Pretty Stable
Non Current Assets Total14.2 M24.5 M6.9 M
Slightly volatile
Non Currrent Assets Other27.1 K28.5 K76 K
Slightly volatile
Other Assets218.8 K384 K127.5 K
Slightly volatile
Cash And Short Term Investments4.4 M4.7 M10.2 M
Pretty Stable
Common Stock Total Equity4.3 K4.1 K1.5 K
Slightly volatile
Common Stock Shares Outstanding40.3 M38.8 M36.9 M
Slightly volatile
Liabilities And Stockholders Equity33.8 M30.2 M19.3 M
Slightly volatile
Non Current Liabilities Total3.8 M7.4 M1.8 M
Slightly volatile
Other Current Assets695.3 K441.7 K748.7 K
Pretty Stable
Other Stockholder Equity62.8 M93.8 M25.3 M
Slightly volatile
Total Liabilities38.9 M37 M7.1 M
Slightly volatile
Property Plant And Equipment Gross27.9 M26.6 M7.1 M
Slightly volatile
Total Current Assets5.4 M5.7 M11.5 M
Pretty Stable
Capital Stock4.2 K4.5 K13.6 M
Slightly volatile
Common Stock3.1 K4.5 K1.5 K
Slightly volatile
Property Plant Equipment13 M12.4 M4.4 M
Slightly volatile
Short and Long Term Debt Total7.4 M13.7 M2.9 M
Slightly volatile
Net Receivables827 K582.2 K1.9 M
Slightly volatile
Inventory1.5 M1.6 M876.6 K
Slightly volatile
Short Term Debt3.3 M6.3 M1.5 M
Slightly volatile
Long Term Debt7.4 M7.4 M6.5 M
Slightly volatile
Capital Surpluse66.4 M74.7 M81.4 M
Slightly volatile
Non Current Liabilities Other11.4 K12.8 K14 K
Slightly volatile
Short and Long Term Debt5.1 M5.7 M6.2 M
Slightly volatile

HCW Biologics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income610.2 K581.2 K215.8 K
Slightly volatile
Depreciation And Amortization838.9 K1.2 M575.7 K
Slightly volatile
Selling General Administrative23 M21.9 M5.7 M
Slightly volatile
Other Operating Expenses20.7 M32 M12.5 M
Slightly volatile
Research Development8 M6.4 M6.1 M
Slightly volatile
Cost Of Revenue2 M1.6 M956.7 K
Slightly volatile
Total Operating Expenses19.1 M30.4 M11.6 M
Slightly volatile
Reconciled Depreciation840.6 K1.2 M576.4 K
Slightly volatile
Selling And Marketing Expenses577.8 K804.9 K301.3 K
Slightly volatile

HCW Biologics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation644.9 K1 M261.1 K
Slightly volatile
Begin Period Cash Flow3.4 M3.6 M4.9 M
Slightly volatile
Depreciation838.9 K1.2 M575.7 K
Slightly volatile
Capital Expenditures248.5 K261.6 K2 M
Pretty Stable
Issuance Of Capital Stock11.6 M6.5 M13.7 M
Very volatile
End Period Cash Flow7.8 M4.7 M8.3 M
Pretty Stable
Dividends Paid2.3 M2.5 M2.8 M
Slightly volatile
Cash And Cash Equivalents Changes8.5 M9.5 M10.4 M
Slightly volatile
Cash Flows Other Operating1.9 M2.1 M2.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2562701.7 K
Slightly volatile
Days Sales Outstanding14482.7895182
Slightly volatile
Average Payables3.5 M3.3 M1 M
Slightly volatile
Stock Based Compensation To Revenue0.410.39310.0968
Slightly volatile
Capex To Depreciation0.210.22093.4525
Very volatile
EV To Sales2592731.7 K
Slightly volatile
Inventory Turnover2.82.670.8981
Slightly volatile
Days Of Inventory On Hand1341421.1 K
Slightly volatile
Payables Turnover0.06840.0721.2185
Very volatile
Sales General And Administrative To Revenue1.832.66461.1344
Slightly volatile
Average Inventory1.1 M802.1 K1.2 M
Slightly volatile
Research And Ddevelopement To Revenue1.642.33711.8077
Pretty Stable
Capex To Revenue0.09680.10190.3712
Slightly volatile
Cash Per Share0.110.12050.2804
Pretty Stable
Days Payables Outstanding5.3 K5.1 K949
Slightly volatile
Income Quality0.450.47390.9031
Slightly volatile
Current Ratio0.180.19237.345
Pretty Stable
Receivables Turnover6.64.40883.9428
Slightly volatile
Capex Per Share0.00640.00670.0548
Pretty Stable
Average Receivables220.3 K247.8 K270.2 K
Slightly volatile
Revenue Per Share0.120.06620.1168
Very volatile
Interest Debt Per Share0.40.38280.0938
Slightly volatile
Debt To Assets0.480.45280.1146
Slightly volatile
Operating Cycle78.6582.7895277
Very volatile
Days Of Payables Outstanding5.3 K5.1 K949
Slightly volatile
Ebt Per Ebit0.791.01850.9768
Slightly volatile
Long Term Debt To Capitalization12.7512.14081.6944
Slightly volatile
Total Debt To Capitalization2.081.9780.3179
Slightly volatile
Quick Ratio0.180.19237.2228
Slightly volatile
Net Income Per E B T1.081.141.0034
Slightly volatile
Cash Ratio0.150.15785.6728
Slightly volatile
Days Of Inventory Outstanding1341421.1 K
Slightly volatile
Days Of Sales Outstanding14482.7895182
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.01.01841.2165
Very volatile
Fixed Asset Turnover0.110.1121.8451
Slightly volatile
Debt Ratio0.480.45280.1146
Slightly volatile
Price Sales Ratio2562701.7 K
Slightly volatile
Asset Turnover0.170.08490.2232
Slightly volatile
Gross Profit Margin0.350.37380.3702
Slightly volatile

HCW Biologics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap657.5 M692.1 M2.9 B
Slightly volatile
Enterprise Value666 M701.1 M2.8 B
Slightly volatile

HCW Fundamental Market Drivers

HCW Upcoming Events

26th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About HCW Biologics Financial Statements

HCW Biologics stakeholders use historical fundamental indicators, such as HCW Biologics' revenue or net income, to determine how well the company is positioned to perform in the future. Although HCW Biologics investors may analyze each financial statement separately, they are all interrelated. For example, changes in HCW Biologics' assets and liabilities are reflected in the revenues and expenses on HCW Biologics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in HCW Biologics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue2.1 M2.2 M
Total Revenue2.6 M3.7 M
Cost Of Revenue1.6 M2 M
Stock Based Compensation To Revenue 0.39  0.41 
Sales General And Administrative To Revenue 2.66  1.83 
Research And Ddevelopement To Revenue 2.34  1.64 
Capex To Revenue 0.10  0.10 
Revenue Per Share 0.07  0.12 
Ebit Per Revenue(11.49)(12.06)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
DDDupont De Nemours
CRDOCredo Technology Group
GOOGAlphabet Inc Class C
When determining whether HCW Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of HCW Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hcw Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hcw Biologics Stock:
How To Invest In HCW
Details
Is HCW Stock a good investment?
Details
What is HCW Biologics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of HCW Biologics Correlation against competitors.
For information on how to trade HCW Stock refer to our How to Trade HCW Stock guide.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of HCW Biologics. If investors know HCW will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about HCW Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(16.41)
Revenue Per Share
0.68
Quarterly Revenue Growth
(0.99)
Return On Assets
(0.30)
Return On Equity
(277.26)
The market value of HCW Biologics is measured differently than its book value, which is the value of HCW that is recorded on the company's balance sheet. Investors also form their own opinion of HCW Biologics' value that differs from its market value or its book value, called intrinsic value, which is HCW Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because HCW Biologics' market value can be influenced by many factors that don't directly affect HCW Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between HCW Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if HCW Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, HCW Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY